Empagliflozin

Generic Name
Empagliflozin
Brand Names
Glyxambi, Jardiance, Synjardy, Trijardy
Drug Type
Small Molecule
Chemical Formula
C23H27ClO7
CAS Number
864070-44-0
Unique Ingredient Identifier
HDC1R2M35U
Background

Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies, for the management of type 2 diabetes mellitus.
...

Indication

Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes, either alone or in combination with metformin or linagliptin. It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease, either alone or a...

Associated Conditions
Cardiovascular Mortality, Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Hospitalizations, Symptomatic Congestive Heart Failure, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
Associated Therapies
Monotherapy
Clinical Trials
Related News

Empagliflozin and Atrial Fibrillation Treatment

First Posted Date
2020-10-12
Last Posted Date
2021-04-02
Lead Sponsor
Miulli General Hospital
Target Recruit Count
400
Registration Number
NCT04583813
Locations
🇮🇹

Miulli General Hospital, Acquaviva Delle Fonti, Bari, Italy

A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years

Phase 4
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Empagliflozin
Drug: Placebo
First Posted Date
2020-08-28
Last Posted Date
2024-05-02
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
129
Registration Number
NCT04531462
Locations
🇯🇵

North Alps Medical Center Azumi Hospital, Nagano, Kitaazumi-gun, Japan

🇯🇵

Shinagawa East one Medical Clinic, Tokyo, Minato-ku, Japan

🇯🇵

Chubu Rosai Hospital, Aichi, Nagoya, Japan

and more 15 locations

A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy

Not Applicable
Conditions
Acromegaly
Cardiomyopathies
Interventions
Drug: Empagliflozin
First Posted Date
2020-08-20
Last Posted Date
2020-08-20
Lead Sponsor
Huashan Hospital
Target Recruit Count
10
Registration Number
NCT04520646
Locations
🇨🇳

Huashan Hospital, Shanghai, Shanghai, China

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

Phase 3
Completed
Conditions
Myocardial Infarction
Interventions
Drug: Placebo
Drug: Empagliflozin
First Posted Date
2020-08-12
Last Posted Date
2023-11-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
6522
Registration Number
NCT04509674
Locations
🇺🇸

Charlotte Heart Group Research Center, Port Charlotte, Florida, United States

🇦🇺

Royal Brisbane and Women's Hospital, Herston, Queensland, Australia

🇺🇸

Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States

and more 427 locations

Empagliflozin and Cardiac Remodelling in People Without Diabetes

First Posted Date
2020-07-08
Last Posted Date
2023-02-17
Lead Sponsor
Unity Health Toronto
Target Recruit Count
169
Registration Number
NCT04461041
Locations
🇨🇦

St. Michael's Hospital, Toronto, Ontario, Canada

🇨🇳

Chang Gung Memorial Hospital, Keelung, Taiwan

🇨🇦

North York Diagnostic and Cardiac Centre, Toronto, Ontario, Canada

and more 1 locations

Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin

First Posted Date
2020-06-16
Last Posted Date
2021-11-15
Lead Sponsor
Handok Inc.
Target Recruit Count
32
Registration Number
NCT04431141
Locations
🇰🇷

Clinical Pharmacology, Asan Medical Center, Seoul, Korea, Republic of

Randomised Evaluation of COVID-19 Therapy

First Posted Date
2020-05-11
Last Posted Date
2024-01-05
Lead Sponsor
University of Oxford
Target Recruit Count
70000
Registration Number
NCT04381936
Locations
🇻🇳

Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam

🇬🇭

Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana

🇮🇳

Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India

and more 4 locations

Pharmacological Reduction of Right Ventricular Enlargement

First Posted Date
2020-04-14
Last Posted Date
2023-07-21
Lead Sponsor
Asan Medical Center
Target Recruit Count
180
Registration Number
NCT04345796
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists

First Posted Date
2020-03-04
Last Posted Date
2024-08-30
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24500
Registration Number
NCT04295005
Locations
🇩🇪

Boehringer Ingelheim, Ingelheim am Rhein, Germany

A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Placebo
Drug: Empagliflozin
First Posted Date
2020-01-18
Last Posted Date
2023-12-15
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
219
Registration Number
NCT04233801
Locations
🇨🇳

Peking University People's Hospital, Beijing, China

🇨🇳

The First Affiliated Hospital of Nanchang University, Nanchang, China

🇨🇳

Centre Hospital of Putuo District, Shanghai, Shanghai, China

and more 21 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy